Conv. Plasma
Nigella Sativa

All casirivimab/imdevimab..
Meta analysis
study COVID-19 treatment researchCasirivimab/imdevimabCasirivimab/i.. (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Lack of Ronapreve (REGN-CoV; casirivimab and imdevimab) virological efficacy against the SARS-CoV 2 Omicron variant (B.1.1.529) in K18-hACE2 mice

Tatham et al., bioRxiv, doi:10.1101/2022.01.23.477397
Jan 2022  
  Source   PDF   All Studies   Meta AnalysisMeta
16th treatment shown to reduce risk in March 2021
*, now with p = 0.000055 from 29 studies, recognized in 45 countries. Efficacy is variant dependent.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 77 treatments.
K18-hACE2 mouse study showing that casirivimab/imdevimab was not effective for omicron at doses 2x higher than those effective for previous variants.
Tatham et al., 24 Jan 2022, preprint, 15 authors.
This PaperCasirivimab/i..All
Lack of Ronapreve (REGN-CoV; casirivimab and imdevimab) virological efficacy against the SARS-CoV-2 Omicron variant (B.1.1.529) in K18-hACE2 mice
Lee Tatham, Joanne Sharp, Edyta Kijak, Joanne Herriott, Megan Neary, Helen Box, Anthony Valentijn, Helen Cox, Henry Pertinez, Paul Curley, Usman Arshad, Rajith Kr Rajoli, Steve Rannard, James Stewart, Andrew Owen
AO and SR are Directors of Tandem Nano Ltd and co-inventors of patents relating to drug delivery. AO has received research funding from ViiV, Merck, Janssen and consultancy from Gilead, ViiV and Merck not related to the current paper. SR has received research funding from ViiV and AstraZeneca and consultancy from Gilead not related to the current paper. No other conflicts are declared by the authors.
Ashraf, Altered sirtuin expression is associated with node-positive breast cancer, British Journal of Cancer, doi:10.1038/sj.bjc.6603384
Bentley, SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-19
Chen, In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains, Nature, doi:10.1038/s41586-021-03720-y
Choudhary, Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody Therapy (Cold Spring Harbor Laboratory
Dejnirattisai, Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum, The Lancet, doi:10.1016/s0140-6736(21)02844-0
Dejnirattisai, leads to widespread escape from neutralizing antibody responses
Hiscox, Khoo, Stewart, Owen, Shutting the gate before the horse has bolted: is it time for a conversation about SARS-CoV-2 and antiviral drug resistance?, Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkab189
Horby, Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Ikemura, Engineered ACE2 counteracts vaccine-evading SARS-CoV-2 Omicron variant (Cold Spring Harbor Laboratory
Keeton, SARS-CoV-2 spike T cell responses induced upon vaccination or infection remain robust against Omicron
Lamontagne, A living WHO guideline on drugs to prevent covid-19, BMJ, doi:10.1136/bmj.n526
Medigeshi, Sub-optimal Neutralisation of Omicron
Neary, Evaluation of intranasal nafamostat or camostat for SARS-CoV-2 chemoprophylaxis in Syrian golden hamsters (Cold Spring Harbor Laboratory
O'brien, Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19
Peter Horby, Hiscox, Chand, Breuer, Sherwood et al., Antiviral drug resistance and the use of directly acting antiviral drugs (DAAs) for COVID-19
Redd, Minimal cross-over between mutations associated with Omicron variant of SARS-CoV-2 and CD8+ T cell epitopes identified in COVID-19 convalescent individuals
Rothenberger, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variants (Cold Spring Harbor Laboratory
Ryan, Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity, Nature communications, doi:10.1038/s41467-020-20439-y
Salzer, Single-dose immunisation with a multimerised SARS-CoV-2 receptor binding domain (RBD) induces an enhanced and protective response in mice (Cold Spring Harbor Laboratory
Torjesen, Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear, BMJ, doi:10.1136/bmj.n2943
Vanblargan, An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies (Cold Spring Harbor Laboratory
Weinreich, REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19, New England Journal of Medicine, doi:10.1056/nejmoa2108163
Who, None
Wölfel, Virological assessment of hospitalized patients with COVID-2019, Nature, doi:10.1038/s41586-020-2196-x
{ 'institution': [{'name': 'bioRxiv'}], 'indexed': {'date-parts': [[2022, 1, 25]], 'date-time': '2022-01-25T03:10:36Z', 'timestamp': 1643080236339}, 'posted': {'date-parts': [[2022, 1, 24]]}, 'group-title': 'Microbiology', 'reference-count': 0, 'publisher': 'Cold Spring Harbor Laboratory', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'short-container-title': [], 'accepted': {'date-parts': [[2022, 1, 24]]}, 'abstract': '<jats:p>The Omicron variant (B.1.1.529) of SARS-CoV-2 has placed enormous strain on global ' 'healthcare systems since it was first identified by South African researchers in late 2021. ' 'Omicron has &gt;50 mutations which mainly occur in the surface spike protein and this has led ' 'to rapid assessment of monoclonal antibodies to assess the impact on virus neutralisation. ' 'Ronapreve has shown potential application in post-exposure prophylaxis, mild/moderate disease ' 'and in seronegative patients with severe COVID19, but several early reports of loss of in ' 'vitro neutralisation activity have been documented. Here, the virological efficacy of ' 'Ronapreve was assessed in K18-hACE2 mice to provide an in vivo outcome. Ronapreve reduced ' 'sub-genomic RNA in lung and nasal turbinate for the Delta variant but not the Omicron variant ' 'of SARS-CoV-2 at doses 2-fold higher than those shown to be active against previous variants ' 'of the virus. These data add to the growing evidence that the effectiveness of Ronapreve is ' 'compromised for the Omicron variant.</jats:p>', 'DOI': '10.1101/2022.01.23.477397', 'type': 'posted-content', 'created': {'date-parts': [[2022, 1, 25]], 'date-time': '2022-01-25T02:55:18Z', 'timestamp': 1643079318000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': [ 'Lack of Ronapreve (REGN-CoV; casirivimab and imdevimab) virological efficacy against the ' 'SARS-CoV 2 Omicron variant (B.1.1.529) in K18-hACE2 mice'], 'prefix': '10.1101', 'author': [ {'given': 'Lee', 'family': 'Tatham', 'sequence': 'first', 'affiliation': []}, {'given': 'Joanne', 'family': 'Sharp', 'sequence': 'additional', 'affiliation': []}, {'given': 'Edyta', 'family': 'Kijak', 'sequence': 'additional', 'affiliation': []}, {'given': 'Joanne', 'family': 'Herriott', 'sequence': 'additional', 'affiliation': []}, {'given': 'Megan', 'family': 'Neary', 'sequence': 'additional', 'affiliation': []}, {'given': 'Helen', 'family': 'Box', 'sequence': 'additional', 'affiliation': []}, {'given': 'Anthony', 'family': 'Valentijn', 'sequence': 'additional', 'affiliation': []}, {'given': 'Helen', 'family': 'Cox', 'sequence': 'additional', 'affiliation': []}, {'given': 'Henry', 'family': 'Pertinez', 'sequence': 'additional', 'affiliation': []}, {'given': 'Paul', 'family': 'Curley', 'sequence': 'additional', 'affiliation': []}, {'given': 'Usman', 'family': 'Arshad', 'sequence': 'additional', 'affiliation': []}, {'given': 'Rajith KR', 'family': 'Rajoli', 'sequence': 'additional', 'affiliation': []}, {'given': 'Steve', 'family': 'Rannard', 'sequence': 'additional', 'affiliation': []}, {'given': 'James', 'family': 'Stewart', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': '', 'authenticated-orcid': False, 'given': 'Andrew', 'family': 'Owen', 'sequence': 'additional', 'affiliation': []}], 'member': '246', 'container-title': [], 'original-title': [], 'link': [ { 'URL': '', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 1, 25]], 'date-time': '2022-01-25T02:55:19Z', 'timestamp': 1643079319000}, 'score': 1, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 1, 24]]}, 'references-count': 0, 'URL': '', 'relation': {}, 'published': {'date-parts': [[2022, 1, 24]]}, 'subtype': 'preprint'}
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop